These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30747704)

  • 21. Effect of dextran on plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) during surgery.
    Eriksson M; Saldeen T
    Acta Anaesthesiol Scand; 1995 Feb; 39(2):163-6. PubMed ID: 7540788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Profound imbalance of pro-fibrinolytic and anti-fibrinolytic factors (tissue plasminogen activator and plasminogen activator inhibitor type 1) and severe bleeding diathesis in a patient with cirrhosis: correction by liver transplantation.
    Kahl BS; Schwartz BS; Mosher DF
    Blood Coagul Fibrinolysis; 2003 Dec; 14(8):741-4. PubMed ID: 14614353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fibrinolysis during cardiac surgery. Release of tissue plasminogen activator in arterial and coronary sinus blood.
    Valen G; Eriksson E; Risberg B; Vaage J
    Eur J Cardiothorac Surg; 1994; 8(6):324-30. PubMed ID: 8086178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intraoperative evolution of coagulation parameters and t-PA/PAI balance in orthotopic liver transplantation.
    Arnoux D; Boutière B; Houvenaeghel M; Rousset-Rouvière A; Le Treut P; Sampol J
    Thromb Res; 1989 Aug; 55(3):319-28. PubMed ID: 2506668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
    Siegbahn A; Ruusuvaara L
    Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coagulofibrinolytic changes in patients with disseminated intravascular coagulation associated with post-cardiac arrest syndrome--fibrinolytic shutdown and insufficient activation of fibrinolysis lead to organ dysfunction.
    Wada T; Gando S; Mizugaki A; Yanagida Y; Jesmin S; Yokota H; Ieko M
    Thromb Res; 2013 Jul; 132(1):e64-9. PubMed ID: 23726093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolution of urokinase-type plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA) in orthotopic liver transplantation (OLT).
    Himmelreich G; Dooijewaard G; Breinl P; Bechstein WO; Neuhaus P; Kluft C; Riess H
    Thromb Haemost; 1993 Jan; 69(1):56-9. PubMed ID: 8446939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sex differences in the determinants of fibrinolytic activity.
    MacCallum PK; Cooper JA; Howarth DJ; Meade TW; Miller GJ
    Thromb Haemost; 1998 Mar; 79(3):587-90. PubMed ID: 9531046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibrinolytic activity during hemodialysis: a biocompatibility-related phenomenon.
    Martin-Malo A; Velasco F; Rojas R; Castillo D; Rodriguez M; Torres A; Aljama P
    Kidney Int Suppl; 1993 Jun; 41():S213-6. PubMed ID: 8320924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of early allograft dysfunction at 30 min of reperfusion in liver transplantation: An intraoperative diagnostic tool with real time assessment of graft function.
    Moore HB; Yaffe H; Pomposelli JJ; Wachs M; Bak T; Kennealey P; Conzen K; Adams M; Pshak T; Choudhury R; Walker C; Schulick A; Ferrell T; Chapman MP; Pomfret EA; Nydam TL
    Am J Surg; 2020 Dec; 220(6):1518-1525. PubMed ID: 32907708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The intra-operative use of trasylol (aprotinin) in liver transplantation.
    Mallett SV; Cox D; Burroughs AK; Rolles K
    Transpl Int; 1991 Dec; 4(4):227-30. PubMed ID: 1723874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension.
    Fogari R; Zoppi A; Salvadeo SA; Mugellini A; Lazzari P; Santoro T; Derosa G
    Hypertens Res; 2011 Apr; 34(4):509-15. PubMed ID: 21179101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
    Cruden NL; Graham C; Harding SA; Ludlam CA; Fox KA; Newby DE
    Thromb Res; 2006; 118(2):189-97. PubMed ID: 16055173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postoperative changes in plasma tissue-type plasminogen activator and type 1 plasminogen activator inhibitor.
    Aoki K; Nishino N; Baba S; Urano T; Takada A
    Surg Today; 1994; 24(12):1039-43. PubMed ID: 7780225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy].
    Zalewska-Rydzkowska D; Rość D; Ponikowska I; Michalski A; Graczykowska-Koczorowska A; Rydzkowski M
    Pol Merkur Lekarski; 2001 Nov; 11(65):414-7. PubMed ID: 11852811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physical activity status and adverse age-related differences in coagulation and fibrinolytic factors in women.
    DeSouza CA; Jones PP; Seals DR
    Arterioscler Thromb Vasc Biol; 1998 Mar; 18(3):362-8. PubMed ID: 9514404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The fibrinolytic system components are increased in systemic sclerosis and modulated by Alprostadil (alpha1 ciclodestryn).
    Bandinelli F; Bartoli F; Perfetto E; Del Rosso A; Moggi-Pignone A; Guiducci S; Cinelli M; Fatini C; Generini S; Gabrielli A; Giacomelli R; Maddali Bongi S; Abbate R; Del Rosso M; Matucci Cerinic M
    Clin Exp Rheumatol; 2005; 23(5):671-7. PubMed ID: 16173244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fibrinolytic parameters, lipid status and lipoprotein(a) in ischemic stroke patients.
    Vucković BA; Djerić MJ; Ilić TA; Canak VB; Kojić-Damjanov SLj; Zarkov MG; Cabarkapa VS
    Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():12-7. PubMed ID: 20229676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus.
    Auwerx J; Bouillon R; Collen D; Geboers J
    Arteriosclerosis; 1988; 8(1):68-72. PubMed ID: 2449156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
    Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.